media – Page 27 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

North China Pharmaceutical’s subsidiary’s recombinant tetanus vaccine approved for clinical trials

On May 15, North China Pharmaceutical(600812) announced that its subsidiary Jintan Company recently received the “Drug Clinical Trial Approval Notice” for the recombinant tetanus vaccine (Escherichia coli) approved and issued by the National Medical Products Administration. The acceptance number of the notice is CXSL2500168, the notice number is 2025LP01313, the dosage form is injection, the specification is 30μg/0.5ml/piece, and the approval conclusion shows that the vaccine meets the relevant requirements for drug registration and agrees to conduct clinical trials. As of April 2025, Jintan’s cumulative R&D expenses for this drug are RMB 39.71 million (unaudited). Currently, there is no recombinant tetanus vaccine based on genetic engineering on the market at home and abroad, and Jintan’s R&D will fill this market gap. In the first quarter of 2025, North China Pharmaceutical achieved revenue of 2.574 billion yuan and net profit attributable to shareholders of the parent company of 57.49 million yuan. ...
- Source: drugdu
- 105
- May 19, 2025
The National Medical Products Administration approved the marketing of velaglucerase beta for injection

On May 15, the National Medical Products Administration approved the marketing of velaglucerase beta for injection (trade name: Gorenin) applied by Beihai Kangcheng (Shanghai) Biotechnology Co., Ltd. through the priority review and approval procedure. It is suitable for long-term enzyme replacement therapy for adolescents and adults with type I and type III Gaucher disease aged 12 and above. Gaucher disease is an autosomal recessive metabolic disease caused by functional defects of glucocerebrosidase in lysosomes and is included in the “First List of Rare Diseases”. Velaglucerase beta for injection can reduce the storage of glucocerebroside in the body, thereby exerting a therapeutic effect. The listing of this variety provides a new treatment option for related patients. 网址：https://finance.eastmoney.com/a/202505153405858055.html
- Source: drugdu
- 102
- May 19, 2025
GlaxoSmithKline to buy Boston Pharmaceuticals unit for up to $2 billion

GlaxoSmithKline and Boston Pharmaceuticals announced on May 14 that they have reached an agreement for GlaxoSmithKline to acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, to obtain the sales rights of Efimosfermin, a Phase III clinical-ready, investigational specialty drug for the treatment of fatty liver disease (SLD). Under the agreement, GlaxoSmithKline will pay an upfront payment of $1.2 billion and may pay additional milestone payments totaling up to $800 million. 网址：https://finance.eastmoney.com/a/202505143404307664.html
- Source: drugdu
- 81
- May 19, 2025
The King of Autoimmune drugs Competition

Previously, Sanofi and Regeneron announced that the FDA has approved a new indication for Dupilumab for the treatment of chronic spontaneous urticaria (CSU) in children and adults aged 12 years and older that is not well controlled with H1 antihistamines. It is worth mentioning that Dupilumab is the first targeted treatment for CSU in the United States in more than a decade. This progress not only consolidates the core position of Dupilumab in the field of autoimmune therapy, but also brings the competition for the “king of autoimmunity” into a white-hot stage. This battle between dragons and tigers for the “autoimmune overlord” has just begun. 1. Self-immunity pioneer The autoimmune field has always been a battleground for pharmaceutical companies, and AbbVie was once the undisputed king of this field. According to Frost & Sullivan data, from the perspective of the global autoimmune market, autoimmune diseases are the second largest drug ...
- Source: drugdu
- 99
- May 19, 2025
Introduction to the new INN naming scheme for monoclonal antibody drugs

The International Pharmaceutical INN Name Expert Group (INN Expert Group) decided to implement a new scheme for naming monoclonal antibody drugs at the 73rd INN Consultative Meeting in October 2021. The new scheme aims to avoid the confusion caused by the use of the “-mab” root in the old naming scheme, divides monoclonal antibody drugs into four different groups, and introduces four completely new root words. 1. Background and purpose of the new naming scheme Old naming scheme: Previously, monoclonal antibody drugs used “-mab” as the root word, but with the development of technology, this naming method can no longer accurately distinguish different types of monoclonal antibodies. New naming scheme: The new scheme divides monoclonal antibody drugs into four groups, each using a unique root word to more accurately describe the characteristics of the drug. 2. Four new root words and their meanings -tug: for “unmodified immunoglobulin” class of mAbs, ...
- Source: drugdu
- 117
- May 19, 2025
China and the United States reduce their reciprocal tariffs to 10%

From May 10 to 11, high-level economic and trade talks between China and the United States were held in Geneva, Switzerland. After the talks, the two sides issued a joint statement today (May 12). The main contents are as follows: The Chinese chief negotiator for China-US economic and trade relations, Vice Premier He Lifeng, and the US chief negotiators, US Treasury Secretary Jeff Bessant and Trade Representative Greer, and other representatives of their respective governments, had candid, in-depth and constructive communication on the implementation of the important consensus reached in the phone call between the Chinese and US heads of state on January 17, and the talks made substantial progress. The United States will (i) modify the additional ad valorem tariffs on Chinese goods (including goods from the Hong Kong Special Administrative Region and the Macao Special Administrative Region) imposed by Executive Order No. 14257 of April 2, 2025, by ...
- Source: drugdu
- 86
- May 19, 2025
InnoCare Pharma holds 7.8 billion

On May 13, InnoCare Pharma released its first quarter 2025 performance report, which opened with a striking cash and related account balance of 7.78 billion yuan. This figure not only lays a solid foundation for the company’s current development, but also paves a broad road for its future strategic layout. InnoCare Pharma’s performance in the first quarter was also outstanding. The company’s revenue increased by 129.9% year-on-year to 380 million yuan, and it successfully achieved a net profit of 14 million yuan, reversing the loss trend of the same period last year. Such outstanding achievements are inseparable from the outstanding contribution of its core products and the efficient promotion of market expansion. The core product Obtunib continued to perform well, with sales revenue increasing by 89.2% year-on-year to RMB 310 million, becoming the core engine of performance growth. After its three major indications, especially marginal zone lymphoma, were included in ...
- Source: drugdu
- 71
- May 19, 2025
The world’s largest superconducting magnet machinery company is aiming for an IPO

Recently, according to the official website of the Shanghai Stock Exchange, the IPO application of Ningbo Jianxin Superconducting Technology Co., Ltd. (hereinafter referred to as Jianxin Superconducting) on the Science and Technology Innovation Board has been accepted. It is worth mentioning that the company has become the third company to be accepted on the Science and Technology Innovation Board in 2025. According to the prospectus, Jianxin Superconducting is mainly engaged in the research and development, production and sales of core components of medical magnetic resonance imaging (MRI) equipment. The company was founded in 2013. After years of development in the MRI industry, its main products are now widely deployed in the MRI field, including superconducting magnets, permanent magnets and gradient coils. In addition, Jianxin Superconducting has mastered a number of core technologies in the MRI field and is committed to implementing the technology. It is worth mentioning that Jianxin Superconducting ...
- Source: drugdu
- 81
- May 19, 2025
Wearable defibrillator patch is approved

Recently, Element Science announced that its wearable defibrillator patch has been approved by the U.S. Food and Drug Administration (FDA) after being approved by British and European regulators early last year. This non-invasive device provides an innovative solution for patients with a temporarily increased risk of cardiac arrest. It is reported that the device is suitable for patients recovering from heart attacks and other patients with serious cardiovascular diseases. The Jewel Patch-WCD wearable cardioverter defibrillator system adopts a lightweight and waterproof design, which supports continuous wear during sleep and showering. The system includes a reusable defibrillator device, a battery pack, and a disposable electrode patch that is replaced once a week. Uday Kumar, President and CEO of Element Science, said that the Jewel patch-type external defibrillator has realized the vision of seamlessly integrating life-saving equipment into patients’ daily lives. This FDA approval not only means the achievement of a regulatory ...
- Source: drugdu
- 98
- May 19, 2025
Discovery of mutated immune cell clones could point to improved treatment for refractory celiac disease

Scientists have identified mutated immune cell clones that could point to improved treatment for refractory celiac disease. Researchers at the Garvan Institute of Medical Research and UNSW Sydney have discovered why some people with celiac disease continue to suffer debilitating symptoms despite strictly avoiding gluten. The study, published in Science Translational Medicine, used cutting-edge single-cell sequencing techniques to reveal that certain immune cells in the gut of these patients carry genetic mutations. The team’s findings suggest these abnormal immune cells are driving ongoing intestinal inflammation that causes symptoms like diarrhoea, pain and malnutrition – pointing to a new way to diagnose and potentially treat the most severe form of celiac disease. Rogue immune cells emerge as hidden culprits celiac disease is a chronic autoimmune condition where the body mistakenly attacks the small intestine in response to gluten, a protein found in wheat, barley and rye. While most people with ...
- Source: drugdu
- 89
- May 19, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.